Navigation Links
Novira Therapeutics Completes $25 Million Series A Financing
Date:3/25/2013

r from chronic HBV infection, with a significant percentage of those individuals dying from long-term complications such as liver cirrhosis or liver cancer. Treatment with nucleotide/nucleoside analogs can effectively suppress viral replication and delay progression of liver disease but does do not typically lead to a sustained virologic response or cure.

About Versant Ventures

Versant Ventures is a leading venture capital firm that specializes in investments in innovative biopharmaceuticals, medical devices and other life science opportunities. Founded in 1999, the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. The firm's successful IPOs include Clovis Oncology, Jazz Pharmaceuticals, Genomic Health, Insulet and Kythera. M&A exits include Amira, LenSX, Acclarent, Cameron Health Ablation Frontiers and Lutonix. In addition to an industry-leading biotech-focused team in Basel, Switzerland and the San Francisco Bay Area, Versant has a presence in two other key geographic locations of Southern California and Minnesota.

For more information visit versantventures.com.

About Novira Therapeutics

Novira Therapeutics, Inc. is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the capsid of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors is rarely curative despite lifelong treatment. Ca
'/>"/>

SOURCE Novira Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
3. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
4. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
5. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
6. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
7. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
8. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
9. United Therapeutics Announces Additional $420 Million Share Repurchase Program
10. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
11. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)... 2015  Epic Sciences announced today that President and ... the 35th Annual Cowen and Company Health Care Conference ... Room, 3rd Floor. The conference will be held at ... Epic is developing diagnostic tests of high clinical ... changes that occur during the course of cancer treatments. ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... Schering-Plough Corporation (NYSE: SGP ) will provide ... P. Koestler, Ph.D., executive vice president and president, Schering-Plough ... Conference in San Francisco on Monday, Jan. 12, at ... is expected to talk about the company,s R&D pipeline ...
... LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., ... that GSK has resubmitted the New Drug Application (NDA) ... approval of Solzira (TM) (gabapentin enacarbil) Extended ... Restless Legs Syndrome (RLS). The FDA had requested ...
... LONDON, January 9 UK medical technology company,BioCeramic ... Stephan Rietiker,has joined the company,s Board of Directors. ... in BioCeramic Therapeutics, targeted sectors,particularly as former President ... follows the recent appointment of another renowned,figure, Sir ...
Cached Biology Technology:GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3Dr Stephan Rietiker Joins BioCeramic Therapeutics 2
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... low levels of an asbestos-like mineral from Montana more ... for lung disease today, according to research from the ... a mineral with a flaky, fluffy-looking structure. Previous studies ... contained increased levels of an asbestos-like mineral fiber that ...
... is full of examples of creatures that try to look ... potential predators. But to avoid being eaten alive the larvae ... a way exchanging a dollar for a couple of dimes. ... dollar larvae created clones of themselves within 24 hours of ...
... Genome Sequencing Center (GSC) at Washington University in St. Louis, ... the corn genome. In the fall of 2005 ... (USDA) and the Department of Energy (DOE), awarded $32 million ... of the project led by the Washington University GSC is ...
Cached Biology News:Low exposure to asbestos-like mineral from Montana vermiculite may up lung disease risk 2Sand dollar larvae use cloning to 'make change,' confound predators 2Sand dollar larvae use cloning to 'make change,' confound predators 3All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
... Cloning Kit enables you to prepare, in ... primary cosmid library of genomic DNA for ... High efficiency cosmid library construction is accomplished ... First, genomic DNA is randomly sheared by ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: